Victory Capital Management
IBB icon

Victory Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Victory Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.6M Sell
211,874
-22,436
-10% -$4.5M 0.03% 604
2026
Q2 		$44.6M Buy
234,310
+8,074
+4% +$1.39M 0.03% 626
2026
Q1 		$38.2M Buy
226,236
+2,926
+1% +$500K 0.02% 641
2025
Q4 		$37.7M Buy
+223,310
New +$36.3M 0.02% 655

Other funds holding IBB

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Commerce Bank
Commerce Bank Kansas City, Missouri $22.9B AUM 22.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
WestEnd Advisors
WestEnd Advisors Charlotte, North Carolina $4.53B AUM 12.98% 1-Year Est. Return

Victory Capital Management's IBB Position: Q3 2026 in Review

Victory Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 9.6% in Q3 2026, selling an estimated $4.5M and leaving 211,874 shares worth $44.6M. The position accounts for 0.03% of the portfolio, ranked #604.

Victory Capital Management first reported a position in IBB in Q4 2025 and has held it in 4 quarters since. 860 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Victory Capital Management held 211,874 shares of iShares Biotechnology ETF worth $44.6M as of Q3 2026.
  • Victory Capital Management sold 22,436 iShares Biotechnology ETF shares in Q3 2026, an estimated $4.5M.
  • iShares Biotechnology ETF made up 0.03% of Victory Capital Management's portfolio in Q3 2026, its #604 holding.
  • Victory Capital Management first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 4 quarters since.
  • 860 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.